Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
Diprivan 1% Injection Emulsion (propofol) 10 mg/mL Injectable Emulsion 50 mL Vial
Medication labelWhy this: Advisory · dailymed-prescription
DIPRIVAN Injectable Emulsion is an IV sedative-hypnotic agent that can be used as described in the table below. Table 3. Indications for DIPRIVAN Injectable Emulsion Safety, effectiveness and dosing guidelines for DIPRIVAN Injectable Emulsion have not been established for MAC Sedation in the pediatric population; therefore, it is not recommended for this use (see PRECAUTIONS, Pediatric Use) . DIPRIVAN Injectable Emulsion is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months because its safety and effectiveness have not been established in those populations. In the Intensive Care Unit (ICU), DIPRIVAN Injectable Emulsion can be administered to intubated, mechanically ventilated adult patients to provide continuous sedation and control of stress responses only by persons skilled in the medical management of critically ill patients and trained in cardiovascular resuscitation and airway management. DIPRIVAN Injectable Emulsion is not indicated for use in Pediatric ICU sedation since the safety of this regimen has not been established (see PRECAUTIONS, Pediatric Use). DIPRIVAN Injectable Emulsion is not recommended for obstetrics, including Cesarean section deliveries. DIPRIVAN Injectable Emulsion crosses the placenta, and as with other general anesthetic agents, the administration of DIPRIVAN Injectable Emulsion may be associated with neonatal depression (see PRECAUTIONS ). DIPRIVAN Injectable Emulsion is not recommended for use in nursing mothers because DIPRIVAN Injectable Emulsion has been reported to be excreted in human milk, and the effects of oral absorption of small amounts of propofol are not known(see PRECAUTIONS ).
- generic_name
- diprivan
- product_names
- Diprivan
- ndc
- 52584-269, 63323-269, 52584-269-50
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en